Doug Drysdale Cybin

Doug Drysdale On How CYB-003 Is Better Than Psilocybin

In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.


Get a Roundup of Psychedelic News Stories in Your Inbox.

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Latest News

Combining Psychedelics: Is It Safe?

Combining Psychedelics: Is It Safe?

Mixing psychedelics goes by many names in pop culture: hippie flipping (MDMA and mushrooms) and candy flipping (MDMA and LSD), to name two. Depending on how you go about it, the experience can be life-affirmingly euphoric or severely overwhelming. But is it ever worth the risk?
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.

Get a Roundup of Psychedelic News Stories in Your Inbox.

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.